Genetic Drifts in PKR-EIF2A Phosphorylation Homology Domain Region in Iranian HCV Positive Patients during Interferon Therapy

Authors

  • Farida Behzadian Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Farzaneh Sabahi Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Maryam Honardust Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Reza Malekzadeh Shariati Hospital
  • Samad Amini-Bavyl-Oleyaee Biotechnology Department, Pasteur Institute of Iran
  • Shahin Merat Shariati Hospital
Abstract:

This article doesn't have abstract

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Interferon Resistance of Hepatitis C Virus Genotypes 1a/1b: Relationship to Structural E2 Gene Quasispecies Mutations

Hepatitis C virus (HCV) envelope glycoprotein-2 (E2) inhibits the interferon (IFN)–induced, double –stranded RNA activated protein kinase (PKR) via PKR eukaryotic initiation factor-2α phosphorylation homology domain (PePHD). Present study examined the genetic variability of the PePHD in patients receiving interferon therapy. The PePHD region from HCV genotype 1a/1b infected patients receiving I...

full text

interferon resistance of hepatitis c virus genotypes 1a/1b: relationship to structural e2 gene quasispecies mutations

hepatitis c virus (hcv) envelope glycoprotein-2 (e2) inhibits the interferon (ifn)–induced, double –stranded rna activated protein kinase (pkr) via pkr eukaryotic initiation factor-2α phosphorylation homology domain (pephd). present study examined the genetic variability of the pephd in patients receiving interferon therapy. the pephd region from hcv genotype 1a/1b infected patients receiving i...

full text

Altered Thymic Function during Interferon Therapy in HCV-Infected Patients

Interferon alpha (IFNα) therapy, despite good efficacy in curing HCV infection, leads to major side effects, in particular inducement of a strong peripheral T-cell lymphocytopenia. We here analyze the early consequences of IFNα therapy on both thymic function and peripheral T-cell homeostasis in patients in the acute or chronic phase of HCV-infection as well as in HIV/HCV co-infected patients. ...

full text

Genotyping Pattern among Iranian HCV Positive Patients

BACKGROUND Successful treatment to eliminate HCV RNA depends on the identified genotype. In the present study, we compared the frequency of different HCV genotypes, during four years study (2004 till 2008). METHODS Sera specimens were received from 16 provinces of Iran. We used High Pure Viral Nucleic Acid Purification kit for extraction and samples were tested with improved form of RT-PCR te...

full text

Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance.

Envelope Protein, and a-Interferon Resistance Taylor et al. (1) showed that the hepatitis C virus (HCV) envelope protein E2 inhibits the activity of the interferon-inducible protein kinase PKR in cell systems. PKR is an antiviral protein that blocks protein synthesis by phosphorylating the translation initiation factor eIF2a (2). HCV E2 binds to PKR through a 12–amino acid sequence similar to t...

full text

Interferon-λ in HCV Infection and Therapy

Chronic infection with hepatitis C virus (HCV) is associated with significant liver disease and is therefore an important public health problem. The current standard-of-care therapy for chronic HCV infection consists of a combination of pegylated (PEG) interferon (IFN)-α and ribavirin. Although this therapy effectively generates a sustained viral response in approximately half of treated indivi...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue None

pages  6- 12

publication date 2008-02

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023